This website is for Private Investors* only

*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

Obtains access to the information in a personal capacity;

Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;

Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;

Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;

Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;

Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.

122.10

12:55 22/02/19

19,309.05

12:55 22/02/19

4,006.65

12:55 22/02/19

3,952.49

12:55 22/02/19

0.53%

20.75

The FTSE 250 aerospace and defence group took a total of £179m in charges, including £150m from the KC-46 air tanker contract with Boeing, which together reflect increased estimates of costs to complete contracts and, in some cases, lower recovery from customers.

The news sent its shares crashing lower by 15.36%.

In parallel, BP and Royal Dutch Shell weighed on the Oil&Gas space after going ex-dividend.

Going the other way, interest rate-sensitive defensive issues were in greatest demand as markets came under pressure from profit-taking following their recent strong run.

Pharmaceuticals led the pack, with stock in Shire putting in the best performance after the drugs firm reported fourth quarter sales and earnings that printed ahead of analysts' forecasts.

Revenues for the quarter came in £3.81bn, versus the consensus $3.77bn, while earnings per share of $3.37 beat the forecast $3.24.

Shares in Vectura also did well after the firm said it hit its royalty cap on sales of GlaxoSmithKline´s Ellipta range of products in 2016, one year ahead of forecasts.

The value of the cap was equivalent to £9.0m.

Among non-life inusrers, it was Lancashire Holdings which did best after it reporting that its bottom line held up in 2016.

Lancashire did caution that "market conditions remain difficult for the foreseeable future" but said it was confident about 2017.

As of 1605 GMT the yield on the benchmark 10-year Gilt was off by three basis points to 1.27%.